Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;91(2):165-175.
doi: 10.1002/ana.26285. Epub 2022 Jan 10.

Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development

Sabrina Paganoni #  1   2 , James D Berry #  1 , Melanie Quintana #  3 , Eric Macklin  4 , Benjamin R Saville  3   5 , Michelle A Detry  3 , Marianne Chase  1 , Alexander V Sherman  1 , Hong Yu  1 , Kristin Drake  1 , Jinsy Andrews  6 , Jeremy Shefner  7 , Lori B Chibnik  4 , Matteo Vestrucci  3 , Merit E Cudkowicz  1 ; Healey ALS Platform Trial Study Group
Collaborators, Affiliations
Review

Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development

Sabrina Paganoni et al. Ann Neurol. 2022 Feb.

Abstract

Current therapeutic development in amyotrophic lateral sclerosis (ALS) relies on individual randomized clinical trials to test a specific investigational product in a single patient population. This approach has intrinsic limitations, including cost, time, and lack of flexibility. Adaptive platform trials represent a novel approach to investigate several interventions for a single disease in a continuous manner. Already in use in oncology, this approach is now being employed more often in neurology. Here, we describe a newly launched platform trial for ALS. The Healey ALS Platform Trial is testing multiple investigational products concurrently in people with ALS, with the goal of rapidly identifying novel treatments, biomarkers, and trial endpoints. ANN NEUROL 2022;91:165-175.

PubMed Disclaimer

References

    1. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012;2012:CD001447.
    1. Takei K, Watanabe K, Yuki S, et al. Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:5-10.
    1. Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004;63:1364-1370.
    1. Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 2019;39:733-748.
    1. Adaptive Platform Trials Coalition. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat Rev Drug Discov 2019;18:797-807.

Publication types